The Drug-Induced Respiratory Disease Website

X. Pulmonary edema

X.b Pulmonary edema, noncardiogenic (NCPE)

XXII. Acute respiratory/cardiorespiratory failure

XXII.b Acute lung injury - ARDS

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.k Pulmonary infiltrates

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.w Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

II. Myocardial dysfunction - Heart failure

II.a Left ventricular dysfunction/failure

III. Myocardial ischemia - Coronary artery disease

III.a Coronary artery disease (acute) - Myocardial ischemia/infarction

XI. Pulmonary vasculopathies

XI.a Pulmonary arterial hypertension

XIV. Pleural involvement

XIV.a Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

IV. Heart block (bundle branch-, AV-block)

IV.a Heart block (bundle branch- or AV-)

XXII. Acute respiratory/cardiorespiratory failure

XXII.e Respiratory failure from ventilatory depression (of neuromuscular cause or causes)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a Pneumonitis (ILD)

XXVIII. Large airway involvement

XXVIII.a Angioedema (may cause UAO, asphyxia and death)

XXXV. Disordered breathing during sleep

XXXV.a Disordered breathing during sleep - Sleep apnea

XXXVI. Autoimmune syndromes - Systemic reactions or conditions

XXXVI.g Generalized myopathy/muscle weakness

XXXVIII. Miscellaneous - Varia

XXXVIII.d Death following exposure or poisoning

XX. Vasculitis

XX.d Vasculitis, pulmonary (w/wo AH), extrathoracic, or systemic: ANCA-positive

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.a Pneumonitis (ILD)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

XIV. Pleural involvement

XIV.k Esophageal pleural fistula

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.h Pulmonary fibrosis (may improve but partly following drug discontinuation)

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.t Focal/localized area of pneumonitis/fibrosis

XXXII. Esophageal pathology

XXXII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula, Boerhaave’s syndrome)

XXVIII. Large airway involvement

XXVIII.a Angioedema (may cause UAO, asphyxia and death)

XXIX. Small airway involvement

XXIX.a Bronchospasm - Wheezing - Asthma

XXIX. Small airway involvement

XXIX.i Exacerbation or deterioration of preexisting COPD

XXXIV. Infections

XXXIV.b Respiratory tract infection incl. pneumonia

XXXVI. Autoimmune syndromes - Systemic reactions or conditions

XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)

XXXVIII. Miscellaneous - Varia

XXXVIII.k Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

IV. Heart block (bundle branch-, AV-block)

IV.a Heart block (bundle branch- or AV-)

XVI. Hemorrhage - Bleeding - Hematoma(s)

XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)

XXII. Acute respiratory/cardiorespiratory failure

XXII.b Acute lung injury - ARDS

XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis

XXIV.ag Chemical (toxic) pneumonitis

XXII. Acute respiratory/cardiorespiratory failure

XXII.e Respiratory failure from ventilatory depression (of neuromuscular cause or causes)